Physician profile
Katelyn Macik
NPI 1679960033
$694.49
in general payments reported to CMS, 2019-2025
14 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.36 · 2024: $21.63 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $188.57 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $89.92 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.20 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $65.02 | 2025 | Unithroid |
| Lilly USA, LLC | $51.30 | 2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $42.14 | 2025 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $34.87 | 2025 | Zoryve |
| Abbvie INC. | $32.42 | 2025 | |
| Abbott Laboratories | $23.36 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $23.02 | 2025 | Enflonsia, Gardasil 9, Capvaxive |
| Inspire Medical Systems, INC. | $18.81 | 2025 | Inspire |
| Amgen INC. | $17.52 | 2025 | Repatha, Otezla |
| Organon LLC | $17.24 | 2025 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.10 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Macik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.